Metabolic and sympathovagal effects of bolus insulin glulisine versus basal insulin glargine therapy in people with type 2 diabetes: A randomized controlled study.
Yumie TakeshitaTakeo TanakaHitomi WakakuriYuki KitaTakehiro KanamoriToshinari TakamuraPublished in: Journal of diabetes investigation (2020)
Both IGlu and IGla regimens reduced glucose variability, with IGlu bringing a greater reduction in M-value. IGla, but not IGlu, increased parasympathetic tone during night-time and decreased sympathetic nerve activity at dawn. These findings shed light on the previously unrecognized role of night-time basal insulin supplementation on sympathovagal activity in type 2 diabetes patients.
Keyphrases
- type diabetes
- glycemic control
- end stage renal disease
- blood glucose
- newly diagnosed
- chronic kidney disease
- ejection fraction
- cardiovascular disease
- prognostic factors
- peritoneal dialysis
- heart rate variability
- blood pressure
- weight loss
- skeletal muscle
- metabolic syndrome
- physical activity
- patient reported
- chemotherapy induced